{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-184867","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.685405+00:00","generated_at":"2026-06-13T10:04:18.413046+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"4D Molecular licenses R100 vector to Astellas for up to $300M per target in ophthalmic gene therapies","bullets":["$20M upfront from Astellas; eligible for up to $42.5M in option/target substitution fees and $300M per target in milestones.","Astellas gains exclusive worldwide license to 4DMT's R100 vector for up to three ophthalmic rare monogenic disease targets.","Tiered royalties from mid-single digits to double-digit sub-teen percentage on net sales; subject to reductions.","Astellas must use commercially reasonable efforts to develop and commercialize in US and at least two major EU markets.","4DMT agreed not to commercialize competing products for 7 years (through July 2030)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-184867","json":"https://secwatch.observer/filing/0001193125-23-184867.json","markdown":"https://secwatch.observer/filing/0001193125-23-184867.md","text":"https://secwatch.observer/filing/0001193125-23-184867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/0001193125-23-184867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523184867/d466246d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:04:18.413046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}